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Downregulation of major histocompatibility complex (MHC) class I expression is an important 
mechanism by which tumors evade classical T  cell-dependent immune responses.  Therefore, a 
system was designed  to  evaluate parameters  for active immunization  against  MHC class  I- 
tumors.  Mice were capable of rejecting a MHC class I-  tumor challenge after immunization 
with an irradiated  granulocyte/macrophage colony-stimulating factor (GM-CSF) transduced MHC 
class I-  tumor vaccine.  This response was critically dependent  on CD4 + T  cells  and natural 
killer (NK) cells, but minimally on CD8 + T  cells. A  strong protective response against MHC 
class  I + variants  of the tumor could be elicited when mice were immunized  with irradiated 
MHC class I + GM-CSF-secreting tumor cells. This response required CD4 + and CD8 + T cells, 
and in addition, elimination of NK cells resulted in outgrowth of tumors that had lost expression 
of at least one MHC class I gene. Finally, class I MHC expression on the vaccinating cells inhibited 
the response generated against a MHC class I-  tumor challenge.  These results demonstrate that 
the host is capable of being immunized against a tumor that has lost MHC class I expression 
and reveal conditions under which distinct  effector cells play a role in the systemic antitumor 
immune response. 
T 
he immune  system is capable of recognizing  and re- 
sponding to tumors via several effector mechanisms. Re- 
cent evidence demonstrates that tumor-specific CTL can be 
generated which recognize tumor antigens presented on the 
cell surface together with MHC class I molecules (1, 2). Such 
neoantigens are peptides derived from endogenously synthe- 
sized proteins which are seen as foreign by the host, either 
as a consequence of mutations that  arise during malignant 
transformation or tumor expression of gene products not nor- 
mally expressed in adult tissues.  The predicted consequence 
of such a T cell-mediated selective pressure is outgrowth of 
tumors that have lost expression of these antigens, or equiva- 
lently, loss of the class I MHC molecules themselves. Indeed, 
reports of diminished class I expression on clinically advanced 
tumors and metastases are consistent with  this idea (3-5). 
Likewise, in the majority of experimental models tested, in- 
troduction of MHC class I genes into MHC class F  ~  tumor 
cells to increase their surface expression results in a decrease 
in in vivo tumorigenicity  (6-9). 
In contrast to T  cell-mediated, MHC-restricted recogni- 
tion of tumor, NK cells are known to be able to kill certain 
tumor cell lines in spite of the fact that  they express little 
or no MHC class I antigen.  The nature of the recognition 
molecules involved in NK-target cell interaction is not well 
understood, although emerging data support the hypothesis 
that  one pathway of NK cell activation occurs as a conse- 
quence of encountering cells that have lost self-MHC expres- 
sion (10). Mechanistically, target expression of class I MHC 
would either mask the NK receptor ligand, precluding acti- 
vation, or alternatively, NK cell engagement with target MHC 
would result in an inactivation signal. In vitro data demon- 
strate that many class I-, NK-sensitive targets are rendered 
resistant to lysis by restoring or increasing MHC class I ex- 
pression (11-13). This recognition appears to be at least par- 
tially haplotype specific,  as expression of allogeneic class I 
molecules on the target still results in sensitivity to NK lysis. 
Recent studies of cloned human NK cell line allospecificity 
demonstrate that the trait of susceptibility to NK lysis is in- 
herited in an autosomal recessive fashion and segregates with 
MHC haplotypes, compatible with the activation signal being 
the failure to encounter self-MHC (14,  15). This pattern of 
NK activation does not appear to be restricted to tumor rec- 
ognition, as NK cell-mediated bone marrow graft rejection 
has been shown to occur when an otherwise MHC-identical 
marrow  graft  lacks  a  single  MHC  locus  of the  recipient 
(16,  17). 
Seemingly at odds with  the in vivo consequence of en- 
hanced tumor MHC expression mentioned above, studies of 
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tumor inocula by syngeneic recipients,  whereas  the MHC 
dass I + wild-type counterparts are tumorigenic (12, 18,  19). 
Similarly, in the B16 murine melanoma model, the ability 
to form lung metastases has been shown to be inversely related 
to the class I MHC expression on the tumor (20). In these 
models, elimination of NK cells results in the loss of the re- 
sponse to MHC  class I-  tumors. 
To examine the interplay of these distinct effector pathways 
in a single tumor system, we used a strategy of immuniza- 
tion with genetically modified tumor vaccines followed by 
live tumor challenge to dissect the role of these different effector 
cells in tumor rejection in vivo as a function of class I MHC 
expression. 
Materiah  and Methods 
Tumor Cells.  B78H1  cells  were obtained  from L.  Graf, Jr. 
(University of Illinois College of Dentistry, Chicago, IL; 21). The 
F10 subline of B16 mdanoma cells (22) was obtained from the Na- 
tional Institutes of Health Depository of Cells and Tissues. Cells 
were cultured in vitro in RPMI media, supplemented with 10% 
FCS, penicillin/streptomycin (50 U/ml), t-glutamine (2 raM), so- 
dium pyruvate (1 raM), and nonessential amino acids (0.1 mM), 
and grown at 37~  5% CO2. All cells were periodically tested 
for, and found to be free of mycoplasma  contamination. 
Detection of MHC Class I mRNA.  B78H1 and B16F10 were 
grown in vitro with or without the addition of recombinant mu- 
fine IFN-~/(100 U/ml for 3 d). Cell were trypsinized and washed 
in serum-free HBSS, and total cellular RNA was isohted from 107 
cells that were denatured in the presence of guanidinium thiocya- 
nate (23). cDNA was prepared by reverse transcriptase reaction using 
standard  procedures (24).  1 gg of cDNA was amplified by PCR 
utilizing a 5' consensus  primer for H-2D  s and H-2K  b (5'-CGC 
GAC GCT GCT GCG CAC AG-3'), and 3' primers specific for 
H-2D  s (5'-TAC AAT CTC GGA GAG ACA TT-3') or H-2K  b 
(5'-TAC AAT CTG GGA GAG ACA GA-3'). Amplification of di- 
hydrofolate reductase  message  served as a positive control using 
the primers 5'-CTC AGG GCT GCG ATT TCG CGC CAA ACT 
and 3'-CTG GTA AAC AGA ACT GCG TCC GAC TAT C. 40 
cycles of amplification was performed on a thermal cycler (Perkin 
Elmer Cetus Corp., Norwalk, C~ 94~  reek, 65~  anneal, 72~ 
extension temperatures for 1 min each time). Reaction products 
were electrophoresed and stained  with ethidium bromide. 
Gene Transfer.  MHC class I variants were created by introduc- 
tion of DNA  as a  coprecipitate with  calcium phosphate  (25). 
H-2D  b expression was achieved using plasmid pMo/D  s (26) which 
contains a H-2D  b genomic segment driven off a MoLTR pro- 
moter. For H-2K  b expression, phsmid pKST.8 (27, 28) containing 
H-2K  b cDNA under a ubiquitin promoter was used. Both vectors 
contain the neomycin-resistance  gene. Control transfections with 
the vectors alone (minus the MHC genes) were also performed. 
A total of 5 gg of plasmid vectors was precipitated, and cells were 
exposed to the precipitate for 14-16 h, washed once with HBSS 
without Ca  2§ or Mg  a+, refed with DMEM with 10% FCS, and 
incubated at 37~  Selection in G418 at 400 gg/mlin RPMI media 
was begun 48 h after cells were exposed to precipitate.  More than 
100 colonies  were pooled for each transfection and expanded in 
culture. Single MHC locus transfectants were stained with mAb 
28-14-8 (anti-H-2D  b) followed by goat anti-mouse IgG3'2aFITC 
(Southern Biotechnology Associates,  Birmingham, AL) or with 
mAb B8-24-3  (anti-K  s) followed by goat anti-mouse IgG1FITC 
(southern Biotechnology Associates).  Double transfectants were 
stained with mAb B8-24-3 followed by goat anti-mouse IgGPE 
(Southern Biotechnology  Associates), unlabeled mouse Ig, and then 
28-14-8 FITC. Positive cells were collected on a FACS  r  (Becton 
Dickinson & Co., Mountain View, CA) recovering >50,000 cells 
per sort. Conformation of purity was performed after in vitro ex- 
pansion, and as many as five sorts were required to obtain popula- 
tions with  homogeneous expression.  GM-CSF production was 
achieved via retroviral transduction of the MHC variants with MFG 
GM-CSF as described (29). All cellular constructs were expanded 
in vitro and aliquots frozen in liquid nitrogen before in vivo studies, 
enabling newly thawed reagents to be used in each experiment. 
GM-CSF Assays.  GM-CSF production was quantified by col- 
lection of tumor supematant (2  x  10  s cells in 5 ml for 24 h) and 
assaying for support of the GM-CSF-dependent cell line NFS-60. 
Dilutions of supematant were transferred to 96-well microtiter plates 
containing 10,000 NFS-60 cells per well. After 48 h, [3H]thymi- 
dine (1 gCi/well) was added for 12 h after which incorporation 
was assessed with a cell harvester.  Units of GM-CSF were calcu- 
lated by comparison to a standard curve generated with recom- 
binant GM-CSF. 
CTL Assay~  Spleens  were removed from BALB/c and C57BL/6 
mice and single cell suspensions  were created by mechanical  dis- 
sociation and passage over nylon mesh. Red cells were removed 
by Ficoll density centrifugation, and lymphocytes were washed and 
counted. BALB/c responder cells were plated in 24-well plates at 
5  x  106 cells/well.  B78HIDbK  b cells or C57BL/6  splenocytes 
were added as stimulators after incubation with mitomycin C (50 
gg/ml for 1 h  at 37~  then three washes in RPMI-10% FCS). 
10 U/m1 of recombinant murine Ib2 was added per well. After 
5 d,  SlCr-release assays were performed as described (30) using 
B78H1 or B78HIDbK  s as targets. 
In Vivo  Protection  Assays.  Cells for injection were harvested from 
in vitro culture by trypsinization after limited expansion and washed 
three times in serum-free HBSS. GM-CSF-producing vaccine cells 
were irradiated (5,000 tad) before injection. All injections were in 
0.1  ml given subcutaneously in the left (vaccine) or right (chal- 
lenge) flank. All experiments included 10 mice per group, and each 
was repeated at least once. Mice were monitored twice weekly, and 
euthanized after the development of tumor. 
In Vivo Antibody Depletions.  In vivo antibody depletions were 
started 1 wk before vaccination, mAb GK1.5 (31) was used f~r CD4 
depletions, mAb 2.43 (32) was used for CD8 depletions, and mAb 
PK136 (33) was used for NK depletion. Ammonium sulfate-purified 
ascites fluid (titered at >1:2,000 by staining of splenocytes on the 
FACS  ~  was  injected intraperitoneally (0.1 ml per mouse) every 
other day for the first week and once per week afterward. Deple- 
tion of lymphocyte subsets was assessed on the day of vaccination, 
the day of live tumor challenge, and weekly thereafter by flow cyto- 
metric analysis of spleen calls stained with 2.43 or GK1.5 followed 
by FITC-labeled goat antibody to rat IgG (Kirkegaard & Perry 
Labortories, Inc., Gaithersburg, MD) or PK136 followed by FITC- 
labeled goat antibody to mouse IgG. For each time point of anal- 
ysis, >99% depletion of the appropriate subset was achieved with 
normal levels of other subsets. 
Results 
B78H1 Does not Express MHC Class I Molecules.  The mu- 
rine mdanoma B78H1 is an amdanotic done of the C57BL/6- 
derived tumor B16 (34). B16 expresses low levels of MHC 
class I molecules, it is not truly MHC dass I-,  and expres- 
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In contrast, B78H1 has been shown to express no detectable 
MHC class I antigen in vitro or after in vivo passage,  and 
such expression is not inducible with IFN-7 (35).  The ab- 
sence of surface expression of MHC class I is due to an ab- 
sence of mRNA transcripts. RNA was isolated from B78H1 
and B16F10 cultured with and without IFN-3'. cDNA was 
prepared by reverse transcriptase reaction, and PCR amplifi- 
cation was performed using H-2D  b,  H-2K  b,  or dihydrofo- 
late  reductase  (DHFR)l-specific  oligonucleotide primers. 
H-2D  b and H-K  b transcripts were evident from B16F10 but 
could not be detected from B78H1,  whereas DHFR  tran- 
scripts were detected in all samples  (Fig.  1). 
Creation of MHC Class I  Variants.  The C57BL/6  strain 
of mice from which these tumors originated expresses only 
two classical MHC class I loci, H-2D b and H-2K  b.  Three 
MHC class I + variants of B78H1 were created via transfec- 
tion of the tumor with either the plasmid vector pMo/D  b 
(containing a neomycin resistance gene and an H-2D  b ge- 
nomic segment), plasmid pKbT.8  (containing a neomycin- 
resistance gene and  an  H-2K  b cDNA),  or both.  Control 
transfections with the vectors minus the MHC genes were 
also performed. Transfectants were selected in the neomycin 
analog G418,  and G418  resistant lines were prepared from 
more than  100 pooled clones of approximately equal size. 
Expanded polyclonal populations were stained with the mAb 
28-14-8  (anti-Db),  B8-24-3  (anti-Kb),  or both, and sorted by 
flow cytometry. Analysis of the sorted transfectants revealed 
heterogeneously  positive populations for the appropriate MHC 
antigens (Fig.  2).  Murine GM-CSF-producing vaccine was 
created by retroviral transduction of the parental class  I- 
B78H1 and the H-2D  b, H-2K  b, and H-2DbK  b variants using 
MFG-murine GM-CSF  (10,000-20,000  U/2  x  10  s cells/ 
24 h), as determined by in vitro bioassay on the GM-CSF- 
dependent cell line NFS-60  (data not shown). 
MHC Class I Expression In Viva  To determine the fidelity 
of MHC dass I expression in vivo,  106 cells of each MHC 
1  Abbreviation used in this  paper: DHFR, dihydrofolate  reductase. 
variants  was  injected  subcutaneously  in  C57BL/6  mice. 
Animals were killed on day 11, and tumor samples were frozen 
in liquid nitrogen and prepared for immunohistochemical 
staining. Representative samples are shown (Fig.  3) and re- 
veal no detectable MHC dass I expression on B78H1, whereas 
the D b and K b variants are positive for the correct locus in 
situ. This result not only confirms the expression of the trans- 
fected  MHC  molecules  in  vivo,  but  also  suggests  that 
unidentified host factors are not inducing MHC class I ex- 
pression in  the B78H1  wild-type tumor. 
H-2b-speci.fic Allogeneic  CTL  Recognize  B78H1  Class I + 
Variants but not B78H1  Wild Type.  Although mAb staining 
confirms that the B78H1 MHC class I transfectants express 
the class I epitope to which the antibody binds, the relevant 
function that the MHC molecule must serve is the ability 
to present antigen to T cells. As a measure of this function, 
an allogeneic CTL assay was performed. BALB/c splenocytes 
(H-2d) were stimulated in vitro with mitomycin C-treated 
C57BL/6  (H-2b) splenocytes, or with B78H1DbK  b.  After 
5 d in culture, the cells were harvested and tested for their 
ability  to  lyse Slchromium-labeled B78H1DbK  b targets  or 
B78H1 wild-type targets.  Significant  anti-B78H1DbK  b CTL 
activity was  detectable after incubation with  either H-2b 
splenocytes or with B78H1DbK  b itself, suggesting that al- 
logeneic T cells were capable of recognizing the transfected 
MHC  dass  I  molecules on B78HIDbK  b (Fig.  4  A).  The 
majority of this in vitro activity was blocked by incubation 
with antibody to CD8. In contrast, the same allogeneic CTL 
had very little activity against  the MHC  class  I-  B78H1 
wild-type targets, and none of this was blocked with anti- 
CD8  antibody  (Fig.  4  B),  indicating  that  CD8 +  T  ceUs 
with  specifidty for  H-2D b and  H-2K  b do  not  recognize 
B78H1. Similarly, B78H1 wild type did not generate a class 
I-specific allogeneic CTL when used as a stimulator cell in 
vitro (data not shown). 
In  Vivo Immune Response to MHC Class I-  Tumor.  Pre- 
vious studies of the systemic antitumor immune response in- 
duced by cytokine-producing tumor vaccines  have revealed 
the dependence on MHC class I-restricted, CD8 + CTL (29, 
30, 36). Given that these effector cells are incapable of recog- 
nizing B78H1 in vitro, we tested the in vivo response against 
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Figure I.  Detection  of  class  I  MHC  mRNA  by  RT- 
PCR.  B78H1  and  B16F10  cells  were  grown  in  the  pres- 
ence  and absence  of  IFN-3,  (100  U/ml) after  which 
total  cellular  RNA  was isolated  and cDNA created 
by  reverse  transcriptase  reaction.  PCR amplification 
was  performed  on  each  sample  using  oligonucleotide 
primers  specific  for  H-2Db,  H-2K  b,  and  dihydrofolate 
reductase.  Reaction  products  were  dectrophoresed  on 
a  0.8% agarose  gel  and stained  with ethidium  bro- 
mide.  Lanes:  (I)  BI6F10,  (2)  BI6F10  IFN-'y-treated, 
(3) B78H1, (4) B78H1 IFN-'y-treated. Lanes: (.4) 
H-2Db primers, (B)  H-2Kb primers, (C)  DHFR 
primers. B78H1 
WILD 
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878H1 
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Figure 2.  Class  I MHC expression  of B78H1 vari- 
ants. Each of the four GM-CSF-producing vaccines 
and four non-GM-CSF-producing chalhnge tumors 
was stained for class I MHC expression  with antibody 
to H-2D  b (mAb 28-14-8 followed  by goat anti-mouse 
IgG2aFITC) and to H-2K  b (mAb B8-24-3 followed 
by goat anti-mouse IgGIFITC) and analyzed  by flow 
cytometry. Also  shown is  the  staining of normal 
C57BL/6  splenocytes for comparison. 
a B78H1 challenge (Fig. 5 A). Remarkably, mice immunized 
with irradiated B78H1GM-CSF were largely protected against 
the MHC class I- tumor challenge at a distant site. Immu- 
nization with irradiated nontransduced B78H1 cells also pro- 
duced some systemic protection against live B78H1 challenge 
but at a much lower level than GM-CSF transduced vaccine. 
To identify which call populations are involved in this re- 
sponse, in vivo lymphocyte subset depletion was performed 
with injections of mAb against CD4 + , CD8 +, or NKI.1 + 
cells  initiated  before  the  immunization  with  irradiated 
B78H1GM-CSF and maintained throughout the experiment 
(Fig. 5 B). Subsequent challenge with B78H1 resulted in tumor 
formation in mice depleted of CD4 + T  ceils and NKI.1 + 
ceils  comparable  to  unimmunized controls,  whereas  the 
CD8 +  T  cell-depleted  group  was  still  significantly pro- 
tected. The effect of CD8 + T  cell depletion was small but 
was seen consistently over three experiments and may repre- 
sent the elimination of a subset  of NK cells that expresses 
CD8.  Given the requirement for CD4 + T  cells in the re- 
sponse to a MHC class I- tumor challenge, explanted tumor 
was stained for expression of MHC class II molecules (Fig. 
6). B78H1 grown in vitro has no detectable MHC class II 
expression by FACS  |  analysis, although expression is induced 
with exposure to IFN-3,. Explanted B78H1 fails to demon- 
strate detectable levels of MHC class II expression. It is there- 
fore unlikely that CD4 + T  calls are acting directly as cyto- 
lytic effector cells. Taken together, these results suggest that 
NK1 + cells are  a major effector cell in the response  to  a 
MHC class I-  tumor challenge,  and that these cells require 
the presence  of CD4 + Th cells that have encountered an- 
tigen on host MHC class II § APCs. 
In  Vivo Immune Response to MHC Class I + Tumor.  We 
next sought to characterize  the in vivo response  against a 
MHC class I + tumor challenge. Mice were immunized with 
irradiated B78HIDbKbGM-CSF and subsequently chaUenged 
with either B78H1D  b,  B78H1K  b,  or B78H1DbK  b (Fig.  7 
A). There was a high level of protection against the MHC 
class I + variants that expressed H-2K  b (B78H1K  b and B78 
HLDbKb),  but  not  H-2D b alone,  suggesting that in  this 
tumor system, an immunodominant antigen(s) recognized 
by class I MHC-restricted T  cells is presented on H-2K  b. 
Selective in vivo lymphocyte subset depletion demonstrated 
that rejection of the MHC class I + tumor B78H1DbK  b also 
required CD4 + T  cells, but in contrast to the MHC class 
I- response, depletion of CD8 + T cells resulted in complete 
loss of protection against B78HLDbK  b (Fig.  7 B). It is in- 
teresting to note that NK1 + cell depletion also resulted in 
the development of tumor outgrowth. Mice from this group 
were killed at the time of tumor detection and the tumors 
were explanted and stained for MHC class I expression (Fig. 
8).  In all cases, tumors that developed  in mice depleted of 
NK1 + cells lost expression  of the dominant T  call restric- 
1218  In Vivo Priming of Two Antitumor Effector Populations: MHC I Expression Figure  3.  MHC Chss I expression of B78H1 variants in vivo. Immunohistochemical  staining  for H-2D  b and H-2K  b was performed on tumor ex- 
phined 11 d after subcutaneous  injection into C57BL/6 mice. Shown are the patterns  with antibody to (top) H-2D  b (mAb 28-14-8); (bottom) H-2Kb 
(mAb B8-24-3) using an avidin-biotin-peroxidase methodology (Vectastain). (A and D) Wild-type B78H1; (B and E) B78H1Dh; and (C and F) B78H1Kb. 
(/3 and F) Strong staining  of the tumor indicating MHC dass  I expression in situ.  The remaining panels show no staining  of the tumors,  although 
positive  staining  is present  on smaller mononuclear cells or endothelial  cells that have infiltrated  the tumor injection site.  x 400. 
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Figure 4.  Recognition of class I MHC expression by allogeneic T cells. BALB/c splenocytes were cultured for 5 d with mitomycin C-treated C57BL/6 
splenocytes or with B78H1DbK b cells in the presence of Ib2.  At the end of the culture,  live cells were mixed with slCr-labeled  targets  at different 
E/T ratios with or without the addition  of anti-CD8 antibody in a 4-h slCr-release assay. (A) Lysis of B78H1DbK b targets.  (B) Lysis of B78H1 wild- 
type targets. 
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(A) Ability of immunized mice to reject a class I MHC- 
tumor challenge. C57BL/6 mice were injected subcutaneously in the left 
flank with 106 irradiated (5,000 tad) B78H1  wild type, or B78H1GM- 
CSF cells, followed 2 wk later by subcutaneous challenge in the right flank 
with 10  s live B78H1 cells. Also shown is B78H1 growth without preim- 
munization. Tumor growth was assessed twice a week by inspection  and 
palpation.  10 mice are included per group. Data are presented as a Kaplan- 
Meier plot. (B) Effect of lymphocyte subset depletion on the protective 
in vivo response  to class I MHC-  B78HIGM-CSF  cells  against  a live 
B78HI challenge. C57BL/6 mice were depleted of CD4 + T cells, CD8 + 
T  cells,  or NKI.1 + cells by intraperitoneal  injections  of purified mAb 
GK1.5, 2.43, or PKD6 respectively. They were then injected subcutane- 
ously with 106 irradiated (5,000 rad) B78HIGM-CSF  cells.  2 wk later, 
they were challenged in the opposite flank with 10  s live B78H1 cells. Also 
shown is the growth of B78H1 cells without subset depletion  or preim- 
munization. 
tion element H-2K b, and often, H-2D b as well.  Tumor loss 
of K b expression  was  also  seen  in  some  of the  few  un- 
depleted mice that failed to be protected. The relative rarity 
of tumor outgrowth in this group compared to those depleted 
of NK1 +  cells,  underscores  the  significance  of NK  cell- 
mediated rejection of tumor that has escaped the CD8 + T 
cell response through the loss of MHC class  I expression. 
MHC Class I Expression on the GM-CSF-producing  Vaccine 
Impairs  the Response  to a MHC  Class  I-  Tumor Challeng~ 
Given the potential for a successful protective response against 
the MHC dass I- tumor challenge, we sought to determine 
how this response is effected by the MHC class  I status of 
B78H1  in vitro,  B78H1 
B78H1  explant  ~  -  interferon) 
\ 
........  0  .....  ...,  .......  .,,,  .......  ', 
lib  1nl  lmlil  i~ali  la 4 
Figure  6.  ExIn~sion of MHC class II antigen on explanted  B78H1 
cells.  B78H1  was excised from the right flank of C57BL/6  mice after 
reaching 1.0 cm. The tumor tissue was minced in media to <l-ram frag- 
ments with scalpel blades and then passed over nylon mesh. Plastic ad- 
herent cells were collected after a 4-h incubation at 37~  5% CO2. Cells 
were stained for expression of I-A  b using the biotinylated  mAb Y3P fol- 
lowed by streptavidin-FITC and analyzed by flow cytometry. Also shown 
is I-A  b expression  of B78H1  grown in vitro  in the presence or absence 
of IFN-7 (100  U/ml for 72 h). 
the immunizing cells. Mice were vaccinated with each of the 
GM-CSF-producing  MHC  class  I variants and challenged 
2 wk later with B78H1 wild type (Fig. 9). Significant pro- 
tection against the MHC class I-  tumor challenge was seen 
when the vaccine expressed no MHC class I antigen, whereas 
vaccination  with  the  MHC  class  I +  variants  of  GM- 
CSF-producing tumor generated a much less protective re- 
sponse.  Although these differences  appear  to be related  to 
the MHC class I status of the vaccinating cells, it is possible 
that this outcome occurred as a consequence of subclone se- 
lection resulting in loss of tumor antigen in the vaccine rela- 
tive  to  the  polyclonal  challenge.  To address  this  concern, 
B78H1GM-CSF was subcloned by limiting dilution.  In ad- 
dition  to four of these clones,  B78H1GM-CSF  transfected 
with each of the control vectors were tested for their ability 
to protect against B78H1 wild type compared to polyclonal 
B78H1GM-CSF  and to B78H1DbKbGM-CSF.  The level  of 
protection against B78H1 wild type achieved by the clones 
and control transfectants  of B78H1GM-CSF was comparable 
to that of polyclonal B78H1GM-CSF,  whereas B7H1DbK b 
GM-CSF protected poorly (data not shown). A  mixing ex- 
periment further demonstrated that MHC class  I § vaccine 
inhibits the generation of a protective response to a MHC 
class  I-  tumor challenge  (Fig.  10).  Mice immunized with 
MHC class  I positive and negative vaccine at separate  sites 
were  protected  against  an  MHC  class  I-  challenge  com- 
parably  to  those  receiving  MHC  class  I-  vaccine  alone. 
However, vaccination with an equal mixture of class I MHC 
positive and negative cells in the same inoculum resulted in 
markedly diminished protection, suggesting that class I MHC 
expression by the vaccinating cells exerts a dominant nega- 
tive  effect  on  the  priming  of the  anti-class  I  MHC-  re- 
sponse. 
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(A)  Effect  of  injection  with  irradiated class  l  MHC + 
B78H1DlbKbGM-CSF calls on the response to challenge with live class 
I MHC + variants of B78H1  tumor. C57BL/6 mice were injected with 
106 irradiated (5,000  rad) B78H1DbKbGM-CSF  cells subcutaneously in 
the left flank.  2 wk later, mice were challenged on the fight flank with 
10  ~ live B78HID b, B78HLK  b, or B78HLDbK  b ceils. Also shown is the 
growth of each of these challenge tumors without preimmunization. (B) 
Effect of lymphocyte subset depletion on the protective in vivo response 
to class I MHC + B78HIDbKbGM-CSF cells against a live B78H1DbKb 
challenge. C57BL/6 mice were depleted ofCD4 + T cells, CD8 + T cells, 
or NKI.1 + calls as in Fig. 6 B, followed by subcutaneous  injection of 106 
irradiated (5,000 rad) B78H1DbK b GM-CSF cells. 2 wk later they were 
injected on the opposite flank with 10  e live B78H1DbKb cells. Also shown 
is the growth of B78HLDbK  b cells without subset  depletion or preim- 
munization. 
Discussion 
These  experiments  identify two  distinct  in vivo effector 
responses to a tumor challenge and illustrate conditions under 
which each predominates. The host is capable of successfully 
responding  to tumor  that has lost MHC  class I  expression 
even though  this event  eliminates the potential for tumor- 
specific  CD8+T  cell-mediated  rejection.  NK1 +  cells  are 
capable of responding  to  such  an  event,  and under  certain 
circumstances, they may complement the T  cell response. Their 
function may be mediated by direct tumor lysis and/or the 
release of cytokines influencing the activation of other cells 
involved in the response. Whereas it has long been appreciated 
that  NK  cells can lyse MHC  class I-  tumor  in vitro,  and 
are involved in  the  in vivo rejection of such  tumor  in un- 
primed recipients, this is the first study to examine the con- 
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Figure 8.  Class I MHC expression  on tumors explanted from mice 
depleted of NK1 + cells. C57BL/6 mice that had been depleted of NK1 + 
cells and challenged with B78H1DbKb as in Fig. 7 B were killed after de- 
veloping tumors of >1 cm in diameter. The tumor tissue was excised and 
processed as in Fig. 6. Cells were stained for expression of H-2D  b (mAb 
28-14-8 followed by goat anti-mouse IgG2aFITC) and H-2K  b (mAb B8- 
24-3  followed by goat anti-mouse IgG1FITC), and analyzed by flow 
cytometry. 
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Figure 9.  Effect of vaccine cell class I MHC expression on the response 
to a class I MHC- challenge. C57BL/6 mice were vaccinated subcutane- 
ously on the left flank with 106 irradiated (5,000 rad) B78HIDbKbGM  - 
CSF, B78HIDbGM-CSF, B78HIKbGM-CSF, or B78HIGM-CSE 2 wk 
later, the mice were challenged on the fight flank with 10  s live B78H1 
wild-type cells and monitored twice weekly for the development of tumor. 
Also shown is growth of B78H1  without preimmunization. 
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Figure  10.  Effect ofcoinjecting class I MHC positive 
and negative tumor vaccine on the response to a class I 
MHC-  tumor challenge. C57BL/6 mice were injected 
subcutaneously with irradiated (5,000 tad) tumor vaccine 
as follows: 106 B78HIGM-CSF  alone,  106 B78HIGM- 
CSF at one site and 106 B78HIDbKbGM-CSF at a second 
site,  a  mixture  of  106  each  of  B78H1GM-CSF  and 
B78H1DbK b GM-CSF at the same site, or 106 B78H1DbK b 
GM-CSF alone. 2 wk later, the mice were challenged at 
a separate site with 10  s B78H1 wild-type cells and moni- 
tored twice weekly for the development of tumor. Also 
shown is the growth of  B78H1 without preimmunization. 
sequences of tumor vaccine immunization on the activation 
of this cell type. The protective effect of a MHC dass I- 
tumor vaccination against a MHC class I- challenge, as weU 
as the impairment of this response when the vaccinating ceUs 
express MHC class I, are consistent with a durable alteration 
in NK1 + cell function. This conclusion is somewhat at odds 
with the operational definition of NK cells as being "capable 
of lysing a variety of tumor ceUs in vitro without any known 
or deliberate sensitization" i.e., that resting cells are "natu- 
rally" functionally active.  In vivo,  however, viral infection 
or strong antigenic stimulation has been reported to lead 
to  both  activation of NK  cells,  and increase in  NK  cell 
number (37). 
Alternatively, the priming of the host response to a MHC 
class I- challenge may be attributable to the level of CD4 + 
T cell help generated. In the GM-CSF tumor vaccine system, 
the central role of CD4 + Th cells may relate to the recruit- 
ment of "professional" APCs to the vaccine site which pro- 
cess and present tumor antigen on MHC class II molecules 
to  CD4 + Th cells  (29).  The activation of tumor-specific 
CD8 + CTL whose TCRs have first been engaged by the ap- 
propriate antigen-MHC complex is dependent upon the local 
secretion of lymphokines such as IL-2 which is the hallmark 
of CD4 + Th function. That most CTL responses require 
Th cells has long been appreciated (38-41). In contrast, this 
relationship to CD4 § Th activation has not been previously 
reported for NK cell function, although both in vitro and 
in vivo data suggest that NK cell activation is enhanced by 
IL-2 and IFN-7 (42,  43). Our results suggest that CD4 + 
Th cell/NK cell interdependence may result in an additional 
degree of target specificity, as primed antigen-specific  CD4 + 
Th cells would only release cytokines after recognition of the 
appropriate antigen presented on MHC class II of APCs in 
the region of a tumor deposit. It is also possible that CD4 + 
T  cells are functioning as cytotoxic effector calls, although 
in this system, the tumor has not been found to express MHC 
class II in vivo. 
The in vivo protection experiments were also performed 
using irradiated, non-GM-CSF-secreting tumor cells as vac- 
cine. These experiments resulted in a similar pattern of pro- 
tection to that reported for the GM-CSF transduced tumor 
vaccine, although the magnitude of the responses was signi- 
ficantly diminished. Thus it appears that the influence of MHC 
class I expression on the nature of the ensuing antitumor 
response is not dependent on GM-CSF,  although in both 
the response to MHC class I positive and negative tumor, the 
total tumor burden successfully rejected is increased by the 
paracrine expression of this cytokine. 
The negative effect of tumor vaccine MHC class I expres- 
sion on the subsequent response to class I-  challenge sug- 
gests that such an encounter with tumor vaccine either fails 
to activate NK cells, or directly inhibits them. This observa- 
tion is consistent with a pattern of NK cell recognition first 
described over 30 yr ago and termed hybrid resistance (for 
reviews see references 44 and 45). Lethally irradiated hybrid 
mice heterozygous at the MHC gene complex can reject bone 
marrow grafts from a homozygous parental donor. Host NK 
calls  have been found to  mediate this  rejection (46).  Im- 
munogenetic analysis has revealed that the determinants for 
hybrid resistance map to the MHC between H-2S (comple- 
ment) and H-2D (47).  The nature of the NK cell recogni- 
tion event remains controversial. The possibility of recessive 
inheritance of the antigens recognized by the F1 recipient on 
the parental graft has led to a search for gene products en- 
coded in the H-2 region that can explain the observed pat- 
tern of graft rejection (hybrid histocompatibility antigens) 
(48). An alternate explanation suggests that NK ceils are in- 
activated upon encountering self-MHC (possibly plus pep- 
tide) on a potential target, the failure of this event leading 
to lysis of the target. This "missing self' hypothesis (49) was 
supported by the ability of mice transgenic for an allogeneic 
class I MHC molecule (H-2D  d) to reject an otherwise ge- 
neticaUy identical nontransgenic bone marrow but not marrow 
expressing H-2D a, formally demonstrating that expression 
of the class I MHC molecule itself can result in graft survival, 
whereas its absence can be recognized by the NK cells of the 
recipient leading to rejection (16). In our model, similar mech- 
anisms may account for the inhibitory effect of MHC class 
I + tumor on the subsequent NK cell-mediated response to 
MHC class I-  tumor. 
One implication of these findings is that in a heteroge- 
neous tumor burden where loss of MHC class I antigens has 
occurred in some fraction of the tumor, the CD8 + T  cell 
response is likely to be inadequate, and strategies of active 
immunotherapy must attempt to recruit alternate cytolytic 
effector ceils such as NK ceils which may facilitate tumor 
1222  In Vivo Priming of Two Antitumor Effector Populations: MHC  I Expression rejection. The use of class I-  vaccinating cells as one com- 
ponent of the therapy may be effective in this setting. More 
generally, such an immunotherapeutic approach must include 
the consideration of a variety of responding cell populations 
and the conditions which affect the ability of each to con- 
tribute to a successful host response. 
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